Display options
Cite
Kennedy J, Walker A, Ellender CM, et al. Outcomes Of Non-Cystic Fibrosis Related Bronchiectasis Post Lung Transplantation. Intern Med J. 2021;doi: 10.1111/imj.15256.
Kennedy, J., Walker, A., Ellender, C. M., Steinfort, K., Martin, C., Smith, C., Snell, G., & Whitford, H. (2021). Outcomes Of Non-Cystic Fibrosis Related Bronchiectasis Post Lung Transplantation. Internal medicine journal, . https://doi.org/10.1111/imj.15256
Kennedy, Jessica, et al. "Outcomes Of Non-Cystic Fibrosis Related Bronchiectasis Post Lung Transplantation." Internal medicine journal vol. (2021). doi: https://doi.org/10.1111/imj.15256
Kennedy J, Walker A, Ellender CM, Steinfort K, Martin C, Smith C, Snell G, Whitford H. Outcomes Of Non-Cystic Fibrosis Related Bronchiectasis Post Lung Transplantation. Intern Med J. 2021 Mar 03; doi: 10.1111/imj.15256. Epub 2021 Mar 03. PMID: 33656222.
Copy Download .nbib Format: NLM
Share it on

Intern Med J. 2021 Mar 03; doi: 10.1111/imj.15256. Epub 2021 Mar 03.

Outcomes Of Non-Cystic Fibrosis Related Bronchiectasis Post Lung Transplantation.

Internal medicine journal

Jessica Kennedy, Anne Walker, Claire M Ellender, Kate Steinfort, Catherine Martin, Catherine Smith, Gregory Snell, Helen Whitford

Affiliations

  1. Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia.
  2. School of Medicine, Dentistry and Health Science, Melbourne University, Melbourne, Australia.
  3. Department of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Australia.
  4. Department of Thoracic Medicine, Royal Adelaide Hospital, South Australia, Australia.
  5. Department of Respiratory & Sleep Medicine, Princess Alexandra Hospital, Brisbane, Australia.
  6. Pubic Health and Preventative Medicine, Monash University, Melbourne, Australia.

PMID: 33656222 DOI: 10.1111/imj.15256

Abstract

BACKGROUND: Lung transplantation is a recognised treatment for end-stage lung disease due to bronchiectasis. Non-CF bronchiectasis and CF are often combined into one cohort, however outcomes for non-CF bronchiectasis patients varies between centres, and in comparison to those for CF.

AIMS: To compare lung transplantation mortality and morbidity of bronchiectasis (non-CF) patients to those with CF and other indications.

METHODS: Retrospective analysis of patients undergoing lung transplantation between 01 January 2008-31 December 2013. Time to and cause of lung allograft loss was censored on 01 April 2018. A case-note review was conducted on a sub-group of 78 patients, to analyse hospital admissions as a marker of morbidity.

RESULTS: 341 patients underwent lung transplantation, 22 (6%) had bronchiectasis compared to 69 (20%) with CF. The 5-year survival for the bronchiectasis group was 32%, compared to CF 69%, obstructive lung disease (OLD) 64%, pulmonary hypertension 62% and ILD 55% (p = 0.008). Lung allograft loss due to CLAD with predominant infection was significantly higher in the bronchiectasis group at 2 years. The rate of acute admissions was 2.24 higher in the bronchiectasis group when compared to OLD (p = 0.01). Patients with bronchiectasis spent 45.81 days in hospital per person year after transplantation compared with 18.21 days for CF.

CONCLUSIONS: Bronchiectasis patients in this study had a lower 5-year survival and poorer outcomes in comparison to other indications including CF. Bronchiectasis should be considered a separate entity to CF in survival analysis. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

Keywords: Bronchiectasis; lung transplantation; morbidity; respiratory tract diseases

Publication Types